High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial

Hutchison, Colin A.; Cockwell, Paul; Moroz, Veronica; Bradwell, Arthur R.; Fifer, Lesley; Gillmore, Julian D.; Jesky, Mark D.; Storr, Markus; Wessels, Julie; Winearls, Christopher G.; Weisel, Katja; Heyne, Nils; Cook, Mark

dc.contributor.author	Weisel, Katja
dc.contributor.author	Heyne, Nils
dc.date.accessioned	2020-05-12T12:46:24Z
dc.date.available	2020-05-12T12:46:24Z
dc.date.issued	2019
dc.identifier.issn	2352-3026
dc.identifier.uri	http://hdl.handle.net/10900/100523
dc.language.iso	en	de_DE
dc.publisher	Elsevier Sci Ltd	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/S2352-3026(19)30014-6	de_DE
dc.subject.ddc	610	de_DE
dc.title	High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial	de_DE
dc.type	Article	de_DE
utue.quellen.id	20190926111821_01996
utue.publikation.seiten	E217-E228	de_DE
utue.personen.roh	Hutchison, Colin A.
utue.personen.roh	Cockwell, Paul
utue.personen.roh	Moroz, Veronica
utue.personen.roh	Bradwell, Arthur R.
utue.personen.roh	Fifer, Lesley
utue.personen.roh	Gillmore, Julian D.
utue.personen.roh	Jesky, Mark D.
utue.personen.roh	Storr, Markus
utue.personen.roh	Wessels, Julie
utue.personen.roh	Winearls, Christopher G.
utue.personen.roh	Weisel, Katja
utue.personen.roh	Heyne, Nils
utue.personen.roh	Cook, Mark
dcterms.isPartOf.ZSTitelID	Lancet Haematology	de_DE
dcterms.isPartOf.ZS-Issue	4	de_DE
dcterms.isPartOf.ZS-Volume	6	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE